Furthermore, the knockout/degradation of menin or treatment with the menin inhibitor SNDX-50469 reduce MLL fusion protein-induced AML cell differentiation and reduces AML cell viability, as well as the Bcl-2 and CDK6 levels, but despite the reduced Bcl-2 levels, the combination of SNDX-50469 with venetoclax or the CDK6 inhibitor abemaciclib has synergistic antileukemic effects for patient-derived AML cells harboring MLL1 rearrangements or NPM1-Ins [192]. Here, BCL2 is linked to acute myeloid leukemia.